Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sunovion To Commercialize Novartis’s COPD Products In US

Executive Summary

Sunovion has secured US rights to Novartis's respiratory inhalers, and will cash in on Novartis's FLAME data in COPD patients which recently helped change treatment guidelines.

You may also be interested in...



Sumitomo Dainippon Shores Business/Pipeline Ahead Of Latuda Cliff

Facing the looming loss of exclusivity for its top product, Sumitomo Dainippon Pharma is looking to its late-stage pipeline and recent product and corporate acquisitions to help plug the hole.

Deal Watch: Bristol And Otsuka Pursue Oncolytic Virus Therapies Via Licensing Deals

Busy stretch before Christmas holidays sees two deals around oncolytic virus therapeutics, a Middle East partnership for Orexigen’s Contrave, immuno-oncology deals involving Pfizer and ElsaLys, and Roche and ImmuNext partnering to develop drugs targeting the VISTA pathway.

Clinical Evidence Concern Over New COPD Update

There has been some criticism of the recent update to COPD management guidelines published by GOLD, with concern over the how much of the changes are based on clinical evidence.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC143406

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel